Published in Diabetes Obes Metab on February 12, 2015
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab (2015) 0.92
Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab (2015) 0.87
Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens: Results of an Interview-Based Survey. J Diabetes Sci Technol (2015) 0.86
One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab (2015) 0.85
Accuracy and Injection Force of the Gla-300 Injection Device Compared With Other Commercialized Disposable Insulin Pens. J Diabetes Sci Technol (2015) 0.82
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab (2015) 0.81
Update on the treatment of type 2 diabetes mellitus. World J Diabetes (2016) 0.79
rDNA insulin glargine U300 - a critical appraisal. Diabetes Metab Syndr Obes (2016) 0.78
Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study. Diabetes Ther (2015) 0.78
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab (2016) 0.78
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab (2016) 0.78
Concepts and clinical use of ultra-long basal insulin. Diabetol Metab Syndr (2016) 0.77
Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open (2016) 0.77
Controlled release of biologics for the treatment of type 2 diabetes. J Control Release (2015) 0.75
Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes. Clin Diabetes (2016) 0.75
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus. Diabetes Ther (2017) 0.75
Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care. Clin Diabetes (2016) 0.75
Concentrated insulins: the new basal insulins. Ther Clin Risk Manag (2016) 0.75
Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives. Patient Prefer Adherence (2016) 0.75
New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin. Curr Diab Rep (2017) 0.75
Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization. Adv Ther (2017) 0.75
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care (2005) 8.80
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care (2003) 7.80
Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care (2005) 3.77
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia (2006) 3.23
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med (2012) 2.80
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care (2014) 2.27
Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med (1990) 2.15
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet (2012) 2.13
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care (2014) 1.95
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care (2014) 1.84
Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl (2009) 1.63
A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. Diabet Med (1988) 1.24
Factors associated with psychological insulin resistance in individuals with type 2 diabetes. Diabetes Care (2010) 1.08
Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry. BMC Endocr Disord (2012) 1.05
Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab (2008) 0.97
Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract (2000) 0.90
The need for better insulin therapy. Diabetes Obes Metab (2013) 0.84
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia (2012) 10.74
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia (2008) 4.62
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care (2001) 2.10
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care (2000) 2.08
Long-term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical office. Patient Educ Couns (1997) 1.76
Hyperglycemia, recognized and unrecognized, as a risk factor for stroke and transient ischemic attacks. Stroke (1982) 1.73
Intensive attention improves glycaemic control in insulin-dependent diabetes without further advantage from home blood glucose monitoring: results of a controlled trial. Br Med J (Clin Res Ed) (1982) 1.61
Familial hyperproinsulinemia: partial characterization of circulating proinsulin-like material. Proc Natl Acad Sci U S A (1979) 1.61
Use of an automated device for alternative site blood glucose monitoring. Diabetes Care (2001) 1.57
The mental efficiency of the elderly person with type II diabetes mellitus. J Am Geriatr Soc (1990) 1.51
Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax (1987) 1.48
Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia (1982) 1.46
A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Res Clin Pract (2011) 1.44
The UK Diabetes Dataset: a standard for information exchange. Diabetes Audit Working Group of the Research Unit of the Royal College of Physicians. British Diabetic Association. Diabet Med (1995) 1.42
Diabetes care in general practice: an approach to audit of process and outcome. Br J Gen Pract (1993) 1.40
Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab (2011) 1.38
A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res (2003) 1.38
A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Diabet Med (1984) 1.37
Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia (1987) 1.36
Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med (2006) 1.33
Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed) (1981) 1.32
Diagnostic confusion in diabetes with persistence of fetal haemoglobin. BMJ (1992) 1.20
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med (2002) 1.20
A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract (2010) 1.10
Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed) (1983) 1.09
A dataset to allow exchange of information for monitoring continuing diabetes care. The Diabetes Audit Working Group. Diabet Med (1993) 1.08
Traditional insulin-use practices and the incidence of bacterial contamination and infection. Diabetes Care (1984) 1.04
A strategy for chronic disease. Lancet (1980) 1.03
Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab (2012) 1.00
Diagnosing the undiagnosed with diabetes. BMJ (1994) 1.00
Prevalence of morning hyperglycaemia: determinants of fasting blood glucose concentrations in insulin-treated diabetics. Diabet Med (1985) 0.99
Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med (1984) 0.99
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med (2006) 0.99
Measurement of free insulin concentrations: the influence of the timing of extraction of insulin antibodies. Diabetologia (1985) 0.99
A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII. Diabetes Care (1984) 0.99
Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med (2013) 0.98
Human insulin. Clin Endocrinol Metab (1982) 0.98
A laboratory trial of two new blood-glucose reflectance meters featuring automatic external calibration. Ann Clin Biochem (1984) 0.97
Identifying the impact of diabetes research. Diabet Med (2006) 0.97
Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Diabet Med (1990) 0.96
Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes. Diabet Med (2010) 0.96
Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology (1991) 0.96
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia (2010) 0.95
Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. Diabetes Care (1982) 0.95
Treatment of diabetes with insulin. From art to science. West J Med (1983) 0.95
Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care (2001) 0.94
A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab (2013) 0.94
Diarrhea in streptozocin-treated rats. Loss of adrenergic regulation of intestinal fluid and electrolyte transport. J Clin Invest (1985) 0.93
Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions. Diabet Med (1988) 0.92
In vivo regulation of liver and skeletal muscle glycogen synthase activity by glucose and insulin. Diabetes (1986) 0.92
Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab (2004) 0.92
Early loss of blue-sensitive color vision in patients with type I diabetes. Diabetes Care (1988) 0.92
A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique. Diabetologia (1982) 0.92
Lack of glucagon response to hypoglycemia in type I diabetics after long-term optimal therapy with a continuous subcutaneous insulin infusion pump. Diabetes (1983) 0.91
The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas). Diabetologia (1982) 0.89
Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens. Diabetes Care (1989) 0.89
Influence of glucocorticoids and growth hormone on insulin sensitivity in humans. Diabet Med (2013) 0.89
The new insulins. Their characteristics and clinical indications. Drugs (1982) 0.88
Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Diabet Med (1990) 0.88
Insulin injection site tissue depths and localization of a simulated insulin bolus using a novel air contrast ultrasonographic technique in insulin treated diabetic subjects. Diabet Med (1992) 0.86
Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med (2006) 0.86
Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes (2007) 0.86
Phrenic neuropathy in association with diabetes. Diabet Med (1992) 0.85
Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin. Lancet (1981) 0.85
Forearm muscle metabolism in primary hypothyroidism. Eur J Clin Invest (1993) 0.84
Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metab (2013) 0.83
Insulin insensitivity and skeletal muscle enzyme activities in response to overinsulinization in the rat. Metabolism (1987) 0.83
[Rotation angioplasty--a new procedure for reopening and dilating blood vessels. Experimental findings]. Z Kardiol (1987) 0.83
Problems and safety of continuous subcutaneous insulin infusion. Diabet Med (1984) 0.83
Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting. Diabetes Obes Metab (2012) 0.83
A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med (2003) 0.83
The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes Res Clin Pract (2005) 0.83
Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats. Diabetologia (1985) 0.83
The composition and nutritional adequacy of subject-selected high carbohydrate, low fat diets in insulin-dependent diabetes mellitus. Am J Clin Nutr (1983) 0.83
Insulin glargine: the first clinically useful extended-action insulin analogue. Expert Opin Pharmacother (2001) 0.82
Human insulin: study of safety and efficacy in man. Br Med J (Clin Res Ed) (1981) 0.82
The effects of a high-carbohydrate low-fat cholesterol-restricted diet on plasma lipid, lipoprotein, and apoprotein concentrations in insulin-dependent (type I) diabetes mellitus. Metabolism (1985) 0.82
Observations on control of glycemia with conventional insulin therapy or continuous subcutaneous insulin infusion. Diabetes (1985) 0.82
Muscle enzyme activity and insulin sensitivity in type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1986) 0.82
The measurement of metabolite exchange across muscle beds. Baillieres Clin Endocrinol Metab (1987) 0.82
An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes. Diabetes Obes Metab (2009) 0.82
Haemostasiological parameters as risk factor for new arterial occlusions in diabetics. Klin Wochenschr (1986) 0.81
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes Obes Metab (2014) 0.81
Cholesteryl ester hydrolytic acitivity of rat liver plasma membrane. Biochim Biophys Acta (1975) 0.81
Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes. Diabetes (1984) 0.81
Insulin sensitivity in hyperthyroidism: measurement by the glucose clamp technique. Clin Endocrinol (Oxf) (1983) 0.81
Liver and muscle insulin sensitivity, glycogen concentration and glycogen synthase activity in a rat model of non-insulin-dependent diabetes. Diabetologia (1988) 0.81
Repeatability of measurements and sources of variability in tests of cardiovascular autonomic function. Br Heart J (1992) 0.80
The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes. J Clin Endocrinol Metab (1984) 0.80
New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime. Lancet (1985) 0.80
Total-body potassium in insulin-dependent diabetes mellitus. Clin Sci (Lond) (1990) 0.80
The effect of intraperitoneal insulin delivery on carbohydrate metabolism in type 1 (insulin-dependent) diabetic patients. Diabetes Res Clin Pract (1992) 0.80
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. Diabet Med (2007) 0.79
The performance of three measures of health status in an outpatient diabetes population. Diabet Med (1993) 0.79
Characterizing blood pressure control in individuals with Type 2 diabetes: the relationship between clinic and self-monitored blood pressure. Diabet Med (2003) 0.79
A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. Diabetes Res Clin Pract (1991) 0.79
Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. Diabete Metab (1989) 0.79